SHELTON, Conn., June 9, 2016 /PRNewswire/ -- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company"), a pioneer in developing nanomedicines that directly attack viruses using biomimicry, announced today that it will present at the LDMicro Invitational Conference in Los Angeles, CA on June 9, 2016.
The presentation by Eugene Seymour, MD, MPH, CEO is scheduled to begin at 10am Pacific Daylight Time and will report recent progress as well as explain the nature of the NanoViricides technology.
NanoViricides is actively developing topical antivirals against several different herpesvirus indications, namely, cold sores caused by HSV-1, genital ulcers caused by HSV-2, shingles caused by VZV (the chickenpox virus), and ocular herpes keratitis. The total market size for these indications is estimated to be several billions of dollars. The Company has previously shown complete survival in lethally infected animals with HSV-1 H129 strain infection. The H129 strain is derived from a clinical strain and is a highly infectious, neurotropic virus that causes very high morbidity. Since then the Company has been engaged in further drug optimization and process engineering developments necessary for performing manufacture under current Good Manufacturing Practices (cGMP). A cGMP product is needed for human clinical trials in the USA.
NanoViricides is one of very few small bio-pharma companies that possess their own pilot scale cGMP manufacturing facilities. NanoViricides believes this internal manufacturing capability helps in rapid progress to clinical trials for all of our novel, industry-leading nanomedicine drug candidates. Internal manufacturing also maximally protects our intellectual property. In addition, our multi-kilogram batch production capacity may allow market entry as a stand-alone pharmaceutical company while enabling early revenues, once a product is licensed.
NanoViricides is also working on developing a broad-spectrum nanoviricide to treat diseases caused by several flaviviruses. These flaviviruses include all four subtypes of dengue viruses, as well as the recent epidemic Zika virus, among others. There are no assurances that this work will lead to an effective drug in a rapid timeframe.
NanoViricides is also developing two broad-spectrum drugs to treat influenza virus infections, namely, Injectable FluCide™ for the treatment of severely ill, hospitalized patients, and Oral FluCide™ for the treatment of our-patients.
The presentation will be available at http://www.nanoviricides.com/investorinfo.html.
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Shingles, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/nanoviricides-to-present-at-the-ldmicro-invitational-conference-300282260.html
SOURCE NanoViricides, Inc.